RESUMEN
Endoscopic ultrasound-guided pancreatic duct drainage (EUS-PDD) is a method of decompressing the pancreatic duct (PD) if unable to access the papilla or surgical anastomosis, particularly in nonsurgical candidates. The 2 types of EUS-PDD are EUS-assisted pancreatic rendezvous (EUS-PRV) and EUS-guided pancreaticogastrostomy (EUS-PG). EUS-PRV should be considered in patients with accessible papilla or anastomosis, while EUS-PG is a comparable alternative in surgically altered foregut anatomy. While technical and clinical successes range from 79% to 100%, adverse events occur in approximately 20%. A multidisciplinary approach that considers the patient's anatomy, clinical indication, and long-term goals should be discussed with surgical and interventional radiology colleagues.
Asunto(s)
Drenaje , Endosonografía , Conductos Pancreáticos , Ultrasonografía Intervencional , Humanos , Drenaje/métodos , Conductos Pancreáticos/cirugía , Conductos Pancreáticos/diagnóstico por imagen , Endosonografía/métodos , Ultrasonografía Intervencional/métodos , StentsRESUMEN
Background and Aims: EUS-guided gastroenterostomy (EUS-GE) is effective in relieving gastric outlet obstruction. Several techniques used to create EUS-GEs have been described. However, these techniques are dependent on passing a guidewire beyond the obstruction. We describe a direct needle-puncture technique that allows for successful EUS-GE creation without a guidewire. Methods: The direct antegrade EUS-GE method often involves passing a guidewire and tube beyond the obstruction to distend the small bowel. An oblique echoendoscope is then positioned in the stomach to locate the distended small bowel. An electrocautery-enhanced lumen-apposing metal stent (LAMS) is used to create the anastomosis. However, in cases when neither endoscope nor guidewire can be passed across the obstruction, the direct needle-puncture technique can be used. With the oblique echoendoscope positioned in the stomach, a collapsed loop of small bowel is located adjacent to the gastric wall. A 19-gauge needle is used to puncture the gastric and small bowel wall. The small bowel is distended with a mixture of saline, methylene blue, and contrast via a standard water pump connected to the needle. An antispasmodic is administered, and an electrocautery-enhanced LAMS is then introduced into the working channel to create a gastroenterostomy using the freehand method. Results: The direct needle-puncture technique was performed in 4 patients for these indications: postsurgical inflammation causing gastric outlet obstruction (case 1), tumor infiltration causing gastric outlet obstruction (cases 2A and 2B), and pancreaticobiliary limb access in a duodenal switch (case 3). The video shows the technique performed in a patient with postsurgical inflammation and a patient with duodenal tumor infiltration. Conclusions: The direct needle-puncture technique is useful for performing gastroenterostomy when the guidewire cannot be passed beyond the obstruction. It can also be used to gain access to a targeted bowel limb in altered anatomy for diagnostic and therapeutic purposes.
RESUMEN
GOALS: To describe the long-term outcomes of patients after EUS-guided gallbladder drainage (EUS-GBD), including those who underwent standardized stent exchanges for permanent plastic stents. BACKGROUND: EUS-GBD has become one of the first-line alternatives for gallbladder decompression, with outcomes and safety profiles comparable to that of percutaneous gallbladder drainage. However, the long-term outcomes of EUS-GBD are not well-described. We report our single-center experience of a large cohort who underwent EUS-GBD. STUDY: Patients who underwent EUS-GBD from August 2014 to December 2022 were included in the study. Patient demographics, comorbidities, and procedure details were recorded. Patients were followed until complete stent removal, end of study period, or death. Short and long-term outcomes include technical and clinical success, stent patency, recurrent cholecystitis, cholecystectomy, and death. RESULTS: During the study period, 128 patients were included. One hundred and one patients had benign indications for EUS-GBD, including cholecystitis and choledocholithiasis. Of those with malignant indications, 23 of 27 had distal malignant biliary obstruction. Technical and clinical successes were 95.3% and 95.1%, respectively. Stents were exchanged for 2 permanent double pigtail plastic stents in 43.0%. The mean stent patency was 421 days (488 d among those still alive) without any recurrent cholecystitis. CONCLUSION: EUS-GBD demonstrates prolonged stent patency and minimal long-term adverse events, particularly among patients who underwent stent exchanges for permanent plastic stents. EUS-GBD is also promising for patients presenting with choledocholithiasis and biliary colic who are not surgical candidates.
Asunto(s)
Drenaje , Endosonografía , Stents , Humanos , Drenaje/métodos , Masculino , Femenino , Persona de Mediana Edad , Anciano , Endosonografía/métodos , Resultado del Tratamiento , Estudios Retrospectivos , Vesícula Biliar/cirugía , Vesícula Biliar/diagnóstico por imagen , Adulto , Anciano de 80 o más Años , Ultrasonografía Intervencional/métodos , Colecistitis/cirugíaAsunto(s)
Enfermedades de las Vías Biliares , Colestasis , Trasplante de Hígado , Humanos , Trasplante de Hígado/efectos adversos , Dilatación , Constricción Patológica/etiología , Constricción Patológica/cirugía , Colestasis/etiología , Colestasis/cirugía , Endoscopía , Colangiopancreatografia Retrógrada Endoscópica , Estudios Retrospectivos , Resultado del Tratamiento , Anastomosis Quirúrgica/efectos adversosRESUMEN
BACKGROUND: Most patients in the surgical intensive care unit (SICU) have anemia and undergo extensive diagnostic laboratory testing (DLT). Consequently, patients undergo RBC transfusion, and many are discharged with anemia, both of which are associated with poorer outcomes. OBJECTIVE: To characterize DLT blood loss in the SICU. MATERIALS AND METHODS: We performed a 1-year retrospective study of 291 patients admitted to a SICU. The number of draws, average volume, and estimated discard volume were recorded, along with clinical and laboratory findings. RESULTS: Patients who underwent greater amounts of DLT had lower hemoglobin levels at discharge (P ≤ .001). Admissions requiring central venous catheter (CVC) access (49.8%) demonstrated significantly higher DLT draws and rates of transfusion. CONCLUSION: Findings from this study suggest that DLT blood loss contributes to anemia in the SICU, and that the presence and duration of CVC leads to increased testing, anemia, and RBC transfusion.
Asunto(s)
Anemia , Catéteres Venosos Centrales , Humanos , Estudios Retrospectivos , Catéteres Venosos Centrales/efectos adversos , Hemorragia , Anemia/diagnóstico , Anemia/terapia , Cuidados CríticosRESUMEN
Fluid collections after abdominal surgeries, particularly pancreatic surgeries, are associated with high morbidity and mortality. Up until recently, percutaneous drainage was the first line therapy, but not without disadvantages, including high maintenance, risk of infection and chronic fistulas, electrolyte losses, and impact on quality of life. Endoscopic ultrasound (EUS)-guided drainage of post-surgical fluid collections (PSFCs) is safe and effective, carrying similar success, adverse event (AE), and recurrence rates as percutaneous drainage. Despite limited data on EUS-guided drainage of PSFCs, especially with regards to direct comparisons to percutaneous drainage, EUS management of these collections is becoming the first-line approach in many expert institutions.
Asunto(s)
Endosonografía , Calidad de Vida , Humanos , Drenaje/efectos adversosRESUMEN
Arterio-enteric fistulas involving pancreas allograft are rare complications of transplantation that manifest as gastrointestinal bleeding. We discuss the case of a 34-year-old patient with failed pancreas transplant who presented with recurrent sentinel bleeding before catastrophic hemorrhage. Multiple endoscopies did not identify the source of bleeding, and subsequent angiography demonstrated a fistulous connection between the transplanted pancreatic artery and the small bowel. A stent graft was placed with immediate stabilization. We provide a review of the literature and discuss the clinical manifestations, diagnosis, and management of arterio-enteric fistulas to highlight the importance of early recognition and intervention in preventing life-threatening bleeding.
RESUMEN
The Chicago Classification of esophageal motility disorders improved the differentiation of achalasia subtypes and tailored treatment. Heller myotomy (HM) and pneumatic dilation are two established treatments for achalasia. Peroral endoscopic myotomy (POEM) has become a third definitive option and is on the rise. Using the National Inpatient Sample (NIS) database, we evaluated patients hospitalized with achalasia and associated surgical and endoscopic interventions from 2013 to 2017 and compared patients undergoing HM versus POEM. The NIS database was queried to include patients with achalasia. Patients who underwent HM, POEM (only 2017 due to lack of distinct procedure code in 2013), pneumatic dilation, or esophagectomy were identified. Adverse events during the hospitalization were also queried using diagnosis codes. From 2013 to 2017, patients hospitalized with achalasia increased from 16 850 to 19 485. There were reductions in the number of esophageal dilations (10.6-5.4%, P < 0.001) and HM (18.7-13.1%, P < 0.001). In 2017, 580 POEMs were performed. Compared with patients undergoing HM in 2017, patients who had POEM had higher mean age > 64 (P = 0.004), Charlson comorbidity index (P < 0.001), disease severity (P < 0.001), and likelihood of mortality (P < 0.001). There were no differences in length of stay, mortality, or total costs between the HM and POEM groups. Patients hospitalized with achlasia increased from 2013 to 2017, possibly due to the growth and accessibility of high-resolution esophageal manometry. As expertise in POEM increases, the number of POEM performed is anticipated to rise with possible further reductions in other treatment modalities for achalasia.
Asunto(s)
Acalasia del Esófago , Miotomía de Heller , Cirugía Endoscópica por Orificios Naturales , Acalasia del Esófago/diagnóstico , Acalasia del Esófago/cirugía , Esfínter Esofágico Inferior , Humanos , Resultado del TratamientoRESUMEN
BACKGROUND & AIMS: The prevalence and significance of digestive manifestations in coronavirus disease 2019 (COVID-19) remain uncertain. We aimed to assess the prevalence, spectrum, severity, and significance of digestive manifestations in patients hospitalized with COVID-19. METHODS: Consecutive patients hospitalized with COVID-19 were identified across a geographically diverse alliance of medical centers in North America. Data pertaining to baseline characteristics, symptomatology, laboratory assessment, imaging, and endoscopic findings from the time of symptom onset until discharge or death were abstracted manually from electronic health records to characterize the prevalence, spectrum, and severity of digestive manifestations. Regression analyses were performed to evaluate the association between digestive manifestations and severe outcomes related to COVID-19. RESULTS: A total of 1992 patients across 36 centers met eligibility criteria and were included. Overall, 53% of patients experienced at least 1 gastrointestinal symptom at any time during their illness, most commonly diarrhea (34%), nausea (27%), vomiting (16%), and abdominal pain (11%). In 74% of cases, gastrointestinal symptoms were judged to be mild. In total, 35% of patients developed an abnormal alanine aminotransferase or total bilirubin level; these were increased to less than 5 times the upper limit of normal in 77% of cases. After adjusting for potential confounders, the presence of gastrointestinal symptoms at any time (odds ratio, 0.93; 95% CI, 0.76-1.15) or liver test abnormalities on admission (odds ratio, 1.31; 95% CI, 0.80-2.12) were not associated independently with mechanical ventilation or death. CONCLUSIONS: Among patients hospitalized with COVID-19, gastrointestinal symptoms and liver test abnormalities were common, but the majority were mild and their presence was not associated with a more severe clinical course.
Asunto(s)
COVID-19 , Enfermedades Gastrointestinales/virología , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , COVID-19/complicaciones , Femenino , Humanos , Masculino , Persona de Mediana Edad , América del Norte , Adulto JovenRESUMEN
Desialylation of platelets results in platelet clearance by the Ashwell-Morrell Receptors (AMR) found on hepatocytes. Studies suggest that oseltamivir phosphate inhibits human sialidases, enzymes responsible for desialylation, extending the lifespan of circulating platelets. We thus evaluated, the effects of oseltamivir on platelet count (PC) following treatment. Of the 385 patients evaluated for influenza, 283 (73.5%) were influenza-infected. Of the 283 infected patients, 241 (85.2%) received oseltamivir (I + O+) while 42 patients did not (I + O-). One hundred two non-infected patients received oseltamivir (I-O+). The two groups receiving oseltamivir (I + O+, I-O+), demonstrated a statistically greater increase in the PC (57.53 ± 93.81, p = .013 and 50.79 ± 70.59, p = .023, respectively) relative to the group that did not (18.45 ± 89.33 × 109/L). The observed increase in PC was statistically similar (p = .61) in both groups receiving oseltamivir (I + O+, I-O+), suggesting that this effect is independent of influenza. Comparing clinical characteristics between responders and non-responders to oseltamivir treatment showed that only duration of oseltamivir treatment (AOR = 1.30, 95% CI 1.05-1.61, p = .015) was associated with a positive PC response. Our findings suggest a correlation between oseltamivir treatment and an increase in PCs. Future studies assessing the possible uses of oseltamivir in medical conditions characterized by diminished or defective thrombopoiesis are warranted.
Asunto(s)
Oseltamivir/sangre , Recuento de Plaquetas/métodos , Anciano , Humanos , Persona de Mediana Edad , Estudios RetrospectivosRESUMEN
BACKGROUND/OBJECTIVES: Gallstones are the leading cause of acute pancreatitis in developed countries. National and international guidelines recommend that a cholecystectomy should be performed during the index hospitalization for acute gallstone pancreatitis. We aimed to delineate the national trends for same-admission cholecystectomy and ERCP for acute gallstone pancreatitis over the last ten years. METHODS: We used the 2004, 2009 and 2014 National Inpatient Sample database including patients with a principal diagnosis of acute pancreatitis and a secondary diagnosis of choledocholithiasis or cholelithiasis. Exclusion criteria were age <18 years and elective admission. Primary outcome was the trend in incidence rate of same admission cholecystectomy from 2004 to 2014. The secondary outcomes were: 10-year trend in 1) Incidence of gallstone pancreatitis, 2) proportion of gallstone pancreatitis compared to all other etiologies of acute pancreatitis, 3) incidence rate of same-admission ERCP, 4) length of hospital stay, and 5) total hospitalization costs and charges. RESULTS: The proportion of admissions during which a same-admission cholecystectomy was performed decreased from 48.7% in 2004 to 46.9% in 2009 to 45% in 2014 (trend pâ¯<â¯0.01). During the same time interval, the percentage of admissions during which an ERCP was performed decreased from 25.1% to 18.7% (Trend pâ¯<â¯0.01). CONCLUSIONS: Adherence to the guidelines for same-admission cholecystectomy for patients admitted with acute gallstone pancreatitis have been declining over the past decade. On the other hand, decline in rate of ERCP in patients with acute gallstone pancreatitis and no signs of cholangitis demonstrates adherence to guidelines in this regard.
Asunto(s)
Colangiopancreatografia Retrógrada Endoscópica/tendencias , Colecistectomía/tendencias , Cálculos Biliares/terapia , Pancreatitis/terapia , Admisión del Paciente/estadística & datos numéricos , Colangiopancreatografia Retrógrada Endoscópica/estadística & datos numéricos , Colecistectomía/estadística & datos numéricos , Bases de Datos Factuales , Femenino , Cálculos Biliares/epidemiología , Cálculos Biliares/etiología , Adhesión a Directriz , Costos de Hospital , Humanos , Tiempo de Internación , Masculino , Persona de Mediana Edad , Pancreatitis/complicaciones , Pancreatitis/epidemiología , Estudios Retrospectivos , Resultado del Tratamiento , Estados Unidos/epidemiologíaRESUMEN
Gastric intestinal metaplasia (GIM) is a premalignant condition that can lead to intestinal-type gastric adenocarcinoma. It is characterized by a change in the gastric mucosa to a small-intestinal phenotype. Infection with Helicobacter pylori is the most common factor associated with GIM. Although GIM is typically a histologic diagnosis, various techniques have been developed to enable the endoscopic identification of GIM. There are presently no widely accepted guidelines on screening and surveillance strategies in patients with GIM in the USA. The aim of this review is to provide an update regarding the problem, diagnosis, and management of GIM in the USA.
Asunto(s)
Manejo de la Enfermedad , Mucosa Gástrica/patología , Tracto Gastrointestinal/patología , Lesiones Precancerosas/diagnóstico , Lesiones Precancerosas/epidemiología , Infecciones por Helicobacter/diagnóstico , Infecciones por Helicobacter/epidemiología , Infecciones por Helicobacter/terapia , Helicobacter pylori , Humanos , Metaplasia/diagnóstico , Metaplasia/epidemiología , Lesiones Precancerosas/terapia , Estados Unidos/epidemiologíaRESUMEN
Malnutrition is a common cause of impeding recovery in patients with acute alcoholic hepatitis (AAH). Previous reports have shown that appropriate nutritional supplementation reduce short and long-term mortality in patients with AAH. Despite these clear recommendations, the element of nutrition in AAH is often neglected. We designed a quality improvement project to evaluate and improve compliance with appropriate nutrition in patients presenting with AAH at our institution. Patients admitted with AAH between December 2015 to December 2016 were included. Our primary outcome was compliance with appropriate nutrition. Secondary outcomes included nutrition consultation and hepatology consultation. A total of fifty-four patients were included. Nine of the 53 patients (17%) received high calorie and high protein diets. Hepatology was consulted in 72% (38/53) of the patients, and 21% (8/38) of these patients received appropriate nutrition as compared to only 8.3% (1/12) in whom hepatology was not consulted. Nutrition was consulted in 55% (29/53) of these patients and 67% (19/28) of those patients received appropriate nutrition. In conclusion, our compliance of appropriate nutrition in AAH is low. Our initial investigation suggests that hepatology and nutrition consultation improved compliance with appropriate nutrition. The next step will be to implement protocolized care for appropriate nutrition in AAH by incorporating consultation of hepatology and nutrition services, assess the effect on adherence to appropriate nutrition, and determine the impact on patient outcomes.
Asunto(s)
Dieta Saludable/normas , Gastroenterólogos/normas , Hepatitis Alcohólica/dietoterapia , Desnutrición/dietoterapia , Estado Nutricional , Nutricionistas/normas , Pautas de la Práctica en Medicina/normas , Enfermedad Aguda , Dieta Rica en Proteínas/normas , Ingestión de Energía , Femenino , Hepatitis Alcohólica/complicaciones , Hepatitis Alcohólica/diagnóstico , Hepatitis Alcohólica/fisiopatología , Humanos , Masculino , Desnutrición/diagnóstico , Desnutrición/etiología , Desnutrición/fisiopatología , Persona de Mediana Edad , Valor Nutritivo , Mejoramiento de la Calidad/normas , Indicadores de Calidad de la Atención de Salud/normas , Derivación y Consulta/normas , Factores de Tiempo , Resultado del TratamientoRESUMEN
BACKGROUND: Liver transplantation (LT) is an important treatment for acute liver failure and end-stage liver disease. In 2002, the model for end-stage liver disease (MELD) score was incorporated to prioritize patients awaiting LT. Although there is data on how the MELD score affects waiting times, there is a paucity of literature regarding other components. We aimed to evaluate the factors affecting LT waiting times in the United States. METHODS: Using the United Network for Organ Sharing (UNOS) database, patients aged 12-75 years listed for LT over the years 2002-2015 were included. Variables tested in the model included patient characteristics, pertinent laboratory values, ABO blood type, region of listing, primary payer, ethnicity, and listing for simultaneous transplantation. RESULTS: A total of 75,771 patients were included in the final analysis. The components of the MELD score were associated with shorter waiting times. Other factors associated with shorter waiting times were the need of mechanical ventilation and region 3 of transplantation. ABO blood type, primary payer, and placement of a transjugular intrahepatic porto-systemic shunt also influenced time on the LT waiting list. CONCLUSIONS: MELD score is utilized in the prioritization of liver allocation, and was expected to predict waiting-list time. Mechanical ventilation and other markers of disease severity are associated with higher MELD scores and thus shorter waiting times. Further research is needed to address reasons for the variation in waiting times between regions and payment systems in an attempt to decrease time to LT, standardize the listing process, and improve patient outcomes.
Asunto(s)
Linfoma de Células B Grandes Difuso/diagnóstico , Linfoma de Células B Grandes Difuso/patología , Neoplasias Gástricas/diagnóstico , Neoplasias Gástricas/patología , Anciano , Antígenos CD20/análisis , Biomarcadores de Tumor/análisis , Biopsia , Endoscopía del Sistema Digestivo , Histocitoquímica , Humanos , Inmunohistoquímica , Masculino , Microscopía , Proteínas Proto-Oncogénicas c-bcl-6/análisisRESUMEN
Vedolizumab is a new humanized monoclonal antibody that has been reserved for those with moderate-to-severe Crohn's disease and ulcerative colitis who have failed immunomodulator and TNF-α antagonist therapy, and for those who have an increased risk for developing progressive multifocal leukoencephalopathy. Because it targets gastrointestinal tract-specific lymphocytes, meta-analyses and integrated studies have shown that vedolizumab causes fewer extraintestinal adverse effects, such as opportunistic infections and malignancies, compared with anti-TNF therapies. We present the case of a patient who developed an ovarian teratoma after initiation of vedolizumab therapy.